Navigation Links
A potential novel drug-target for colorectal cancer treatment comes from the brain
Date:4/26/2011

Porto Alegre, Brazil- Tumor progression is usually ensured by more than one proliferative mechanism. When one of these is shut down by a specifically targeted drug, other mechanisms may emerge. While these events may lead to treatment failure, they may also become an opportunity for researchers to identify novel targets to be further explored. In a paper recently published in the journal Oncology ("BDNF/TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer," Vol. 79, pages 430�, 2011; DOI: 10.1159/000326564) Roesler and colleagues describe a novel potential drug-target in colorectal cancer.

Colorectal cancer (CRC) is the fourth most common cancer in men and the third in women worldwide. It is a frequent cancer, with more than 1 million new cases every year and a poor survival rate. Rapid increases in CRC incidence have been observed mainly in emerging economies. These increases are attributed to changes in diet, life style, and patterns of physical activity. In Western countries, only 55% of the patients are alive 5 years after diagnosis, with most patients dying from metastatic disease.

Although a number of treatment options are available for CRC patients, including surgery, chemotherapy and biologic therapies targeting two different mechanismsangiogenesis (bevacizumab) and epidermal growth factor receptors (cetuximab and panitumumab)new treatment options are required to improve survival rates.

The search for novel targets led Dr. Rafael Roesler at the Federal University of Rio Grande do Sul (UFRGS) Brazil, Dr. Gilberto Schwartsmann, and graduate student Caroline Brunetto de Farias, among others, to investigate whether a brain-derived protein known to be involved in tumor growth, metastasis and drug resistance in a number of cancers, including some non-neurological cancers, could also be found in CRC.

The team led by Dr. Roesler found that the brain protein, known as brain-derived neurotrophic factor (BDNF), is present in greater amounts in colorectal tumors when compared to the normal tissue of the same patient. BDNF's receptor, a tropomyosin receptor kinase B (TrkB), is also found in CRC.

The study also shows that BDNF is potentially involved in CRC progression and CRC resistance to drugs targeted at another protein known as the gastrin-releasing peptide, or GRP. By blocking GRPR (which is GRP's receptor) with RC-3095, an antagonist molecule that inhibits proliferation in colorectal cancer cells, expression levels of BDNF may increase. Dr. Roesler and colleagues observed that when levels of BDNF were higher RC-3095-treated colorectal cells still proliferated, indicating that BDNF inhibits the anti-proliferative effects of RC-3095. On the other hand, blockage of BDNF receptor TrkB rescues the anti-proliferative effects of RC-3095. These findings suggest that BDNF is associated with a compensatory response mechanism aimed at maintaining higher proliferative levels characteristic of tumor progression.


'/>"/>

Contact: Dr. Rafael Roesler
rroesler@terra.com.br
55-519-115-9274
Publicase Comunicao Cientfica
Source:Eurekalert

Related medicine news :

1. Marker of Ewing sarcoma: Potential new drug target?
2. Allegheny General Hospital Study Demonstrates Safety and Potential Efficacy of Oral Allergy Treatment
3. MSU researcher links potentially deadly infection, frequent cow exposure
4. Spanish Only, Please: Special Latino Clinic Launched For Potential Abdominal Transplant Patients
5. ACR, SBI: Avon Survey Reveals Potentially Deadly Effects of USPSTF Mammography Recommendations
6. Morgan & Morgan's Personal Injury Attorneys Provide Information About Yaz, Yasmin, and Ocella Injuries and Potential Health Risks
7. International Medical Corps Emergency Response Team on Standby as It Monitors Situation in Chile and Potential Tsunami Areas
8. New testing method hints at garlics cancer-fighting potential
9. Research identifies potential new use for cancer treatment
10. Midroog Ltd., an Affiliate of Moodys Investors Services, Rates Potential new Debt of Elbit Imaging
11. Innovative Service Revolutionizes How Businesses Research Product Sales Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... States of America (PRWEB) , ... May 28, 2016 , ... ... SuperCloset knows all too well the day to day issues, struggles and obstacles ... military. The Helping Veterans Grow Project provides active or retired military veteran(s) with ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the Multiple ... The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the ... United Kingdom came together to explore the many pathways individuals use to get into and ...
(Date:5/27/2016)... ... ... Southland Log Homes , designer and manufacturer of America’s Favorite Log ... be found on its website at SouthlandLogHomes.com. , The designs of the wood ... craftsmanship of timber post and beam construction. The result is a barn that ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... An ... returns for a third time to shed lights on the variety of topics detailing ... inspirational stories, “Nurse Appreciation” tackles why this career has gone from being in a ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational ... by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also ... advocates, associations and industry leaders such as Bioness. , As patients feel ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 31, 2016 RnRMarketResearch.com adds "Asthma ... comparative analysis of Asthma therapy at various stages, therapeutics ... of administration (RoA) and molecule type, along with latest ... reviews key players involved in the therapeutic development for ... Complete report on H1 2016 pipeline review ...
(Date:5/30/2016)... 30, 2016 On 28 May, 194 ... by 2030. At the 69 th World Health Assembly, ... Hepatitis Strategy, signalling the greatest global commitment in viral hepatitis ... eliminating hepatitis B and C by 2030 and includes a ... reduce annual deaths by 65% and increase treatment to 80%, ...
(Date:5/27/2016)... LabStyle Innovations Corp . ( NASDAQ: DRIO ... that the Company,s Chief Financial Officer, Zvi Ben-David ... 1-2 in New York, NY and ... Los Angeles, CA. During his ... including the U.S. FDA Clearance and commercial launch of the ...
Breaking Medicine Technology: